Chlorproguanil
Chlorproguanil[edit]
Chlorproguanil is an antimalarial drug that has been used in the treatment and prevention of malaria. It is a biguanide derivative and functions as a dihydrofolate reductase inhibitor, disrupting the folate pathway in Plasmodium parasites, which are responsible for causing malaria.
Mechanism of Action[edit]
Chlorproguanil works by inhibiting the enzyme dihydrofolate reductase (DHFR) in the malaria parasite. This enzyme is crucial for the synthesis of tetrahydrofolate, a form of folate that is necessary for the synthesis of nucleic acids and amino acids. By blocking DHFR, chlorproguanil effectively halts the replication of the parasite within the human host.
Clinical Use[edit]
Chlorproguanil has been used in combination with other antimalarial drugs to enhance its efficacy. One such combination is with dapsone, known as Lapdap. This combination was used to treat Plasmodium falciparum malaria, particularly in regions where resistance to other antimalarial drugs, such as chloroquine, is prevalent.
Resistance[edit]
Resistance to chlorproguanil can occur through mutations in the DHFR gene of the malaria parasite. These mutations reduce the binding affinity of chlorproguanil to the enzyme, thereby diminishing its effectiveness. Monitoring and managing drug resistance is a critical aspect of malaria control programs.
Safety and Side Effects[edit]
Chlorproguanil, like many antimalarial drugs, can have side effects. Common side effects include nausea, vomiting, and abdominal pain. In some cases, more severe reactions can occur, necessitating careful monitoring of patients during treatment.
Discontinuation[edit]
The use of chlorproguanil, particularly in combination with dapsone, has been discontinued in many regions due to concerns over safety and the development of resistance. Newer antimalarial therapies have been developed that offer improved efficacy and safety profiles.
